386 related articles for article (PubMed ID: 6439866)
1. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis.
Scherak O; Smolen JS; Mayr WR; Mayrhofer F; Kolarz G; Thumb NJ
J Rheumatol; 1984 Oct; 11(5):610-4. PubMed ID: 6439866
[TBL] [Abstract][Full Text] [Related]
2. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis.
Bensen WG; Moore N; Tugwell P; D'Souza M; Singal DP
J Rheumatol; 1984 Jun; 11(3):358-61. PubMed ID: 6234391
[TBL] [Abstract][Full Text] [Related]
3. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
Wooley PH; Griffin J; Panayi GS; Batchelor JR; Welsh KI; Gibson TJ
N Engl J Med; 1980 Aug; 303(6):300-2. PubMed ID: 6770269
[TBL] [Abstract][Full Text] [Related]
4. HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA.
Pachoula-Papasteriades C; Boki K; Varla-Leftherioti M; Kappos-Rigatou I; Fostiropoulos G; Economidou J
Dis Markers; 1986 Jun; 4(1-2):35-41. PubMed ID: 3133153
[TBL] [Abstract][Full Text] [Related]
5. A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis.
Dequeker J; Van Wanghe P; Verdickt W
J Rheumatol; 1984 Jun; 11(3):282-6. PubMed ID: 6376799
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis.
Speerstra F; Reekers P; van de Putte LB; Vandenbroucke JP; Rasker JJ; de Rooij DJ
J Rheumatol; 1983 Dec; 10(6):948-53. PubMed ID: 6420562
[TBL] [Abstract][Full Text] [Related]
7. D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3.
Emery P; Panayi GS; Huston G; Welsh KI; Mitchell SC; Shah RR; Idle JR; Smith RL; Waring RH
J Rheumatol; 1984 Oct; 11(5):626-32. PubMed ID: 6334741
[TBL] [Abstract][Full Text] [Related]
8. Genetic markers in rheumatoid arthritis relationship to toxicity from D-penicillamine.
Stockman A; Zilko PJ; Major GA; Tait BD; Property DN; Mathews JD; Hannah MC; McCluskey J; Muirden KD
J Rheumatol; 1986 Apr; 13(2):269-73. PubMed ID: 3459889
[TBL] [Abstract][Full Text] [Related]
9. HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
Dahlqvist SR; Ström H; Bjelle A; Möller E
Clin Rheumatol; 1985 Mar; 4(1):55-61. PubMed ID: 3157529
[TBL] [Abstract][Full Text] [Related]
10. Histocompatibility antigens in adult obliterative bronchiolitis with or without rheumatoid arthritis.
Sweatman MC; Markwick JR; Charles PJ; Jones SE; Prior JM; Maini RN; Turner-Warwick ME
Dis Markers; 1986 Jun; 4(1-2):19-26. PubMed ID: 3133152
[TBL] [Abstract][Full Text] [Related]
11. [HLA antigens and side effects of gold and D-penicillamine in chronic polyarthritis].
Scherak O; Smolen JS; Mayr WR; Mayrhofer F; Kolarz G; Thumb N
Wien Klin Wochenschr Suppl; 1984; 156():51-2. PubMed ID: 6442059
[No Abstract] [Full Text] [Related]
12. Can gold therapy be used more safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status.
Shah P; Griffith SM; Shadforth MF; Fisher J; Dawes PT; Poulton KV; Thomson W; Ollier WE; Mattey DL
J Rheumatol; 2004 Oct; 31(10):1903-5. PubMed ID: 15468351
[TBL] [Abstract][Full Text] [Related]
13. HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis.
Speerstra F; Reekers P; van de Putte LB; Vandenbroucke JP
Tissue Antigens; 1985 Jul; 26(1):35-40. PubMed ID: 3929421
[TBL] [Abstract][Full Text] [Related]
14. HLA and disease manifestations in rheumatoid arthritis--a Canadian experience.
Gladman DD; Anhorn KA
J Rheumatol; 1986 Apr; 13(2):274-6. PubMed ID: 3459890
[TBL] [Abstract][Full Text] [Related]
15. Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate.
Rodriguez-Pérez M; González-Dominguez J; Matarán L; Garcia-Pérez S; Salvatierra D
J Rheumatol; 1994 Jan; 21(1):41-3. PubMed ID: 8151585
[TBL] [Abstract][Full Text] [Related]
16. [HLA system and complications of the treatment of rheumatoid polyarthritis with D-penicillamine].
Bardin T; Dryll A; Ryckewaert A
Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):27-9. PubMed ID: 3486448
[TBL] [Abstract][Full Text] [Related]
17. A method of comparing the toxicities of disease suppressive agents: possible application to a comparison between D-penicillamine and chloroquine.
Redda A; Anastassiades T
Clin Invest Med; 1984; 7(1):65-71. PubMed ID: 6426836
[TBL] [Abstract][Full Text] [Related]
18. Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens.
Moens HJ; Ament BJ; Feltkamp BW; van der Korst JK
J Rheumatol; 1987 Dec; 14(6):1115-9. PubMed ID: 3437418
[TBL] [Abstract][Full Text] [Related]
19. The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy.
Billingsley LM; Stevens MB
Johns Hopkins Med J; 1981 Feb; 148(2):64-7. PubMed ID: 7206401
[TBL] [Abstract][Full Text] [Related]
20. [HLA DR7 as a protective factor against gold salt toxicity in rheumatoid arthritis].
Rodríguez Pérez M; González Domínguez J; Matarán Pérez L; Salvatierra Ríos D
An Med Interna; 1993 Oct; 10(10):484-6. PubMed ID: 8136425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
